ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0811

Reliability of CRP as an Inflammatory Marker in Patients with Immune Mediated Inflammatory Diseases (IMIDs) and Liver Dysfunction

Yael Ross1 and Stanley Ballou2, 1Case Western Reserve University at MetroHealth Medical Center, Atlanta, GA, 2Case Western Reserve University - Metro Health, Cleveland, OH

Meeting: ACR Convergence 2022

Keywords: autoimmune diseases, Biomarkers, C-reactive protein (CRP), Disease Activity, Inflammation

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster II

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: C-reactive protein (CRP) is an acute-phase reactant widely employed clinically as a marker of inflammation. Serum CRP level is generally elevated with any type of inflammation including infections and IMIDs. CRP is a protein synthesized by hepatocytes. Previous studies have shown lower CRP levels in response to infections in patients with chronic liver disease. We hypothesized that CRP levels would also be lower during active IMIDs in patients with liver dysfunction.

Methods: This retrospective cohort study used Slicer Dicer in Epic, our EMR system, to search for patients with IMIDs both with liver disease over the course of 10 years and without concomitant liver disease over the course of 1 year. Patients with liver disease were excluded if there was no clear documentation of liver disease staging (via MELD score, Child-Pugh score, fibroscan, fibrosure or liver biopsy). Patients were also excluded if a CRP level was not available during disease flare or active disease. Flare or active disease was determined by provider documentation. We arbitrarily considered normal CRP as 0.7mg/dL or lower, mild elevation of CRP as ≥0.8mg/dL and < 3mg/dL, and elevated CRP as ≥3mg/dL.

Results: We identified 68 patients with both liver disease and IMIDs (RA, PsA, PMR) and 296 patients with autoimmune disease without liver disease. Presence of liver disease had the lowest odds ratio (OR 0.25 p< 0.0001) of having an elevated CRP during flare. Each specific IMID, except SLE and IBD, had higher median CRP levels during active disease episodes in patients without liver disease than those with liver disease.

Conclusion: Overall, IMID patients with liver disease had lower serum CRP levels during active disease than their counterparts without liver dysfunction. This observation has implications for clinical use of CRP level as a reliable marker of disease activity in patients with IMIDs and liver dysfunction.

Supporting image 1

Table 1. Patient Demographics.

Supporting image 2

Figure 1. Flare CRP by autoimmune disease with and without liver disease.

Supporting image 3

Table 2. Odds ratio of elevated CRP during disease flare.


Disclosures: Y. Ross, None; S. Ballou, None.

To cite this abstract in AMA style:

Ross Y, Ballou S. Reliability of CRP as an Inflammatory Marker in Patients with Immune Mediated Inflammatory Diseases (IMIDs) and Liver Dysfunction [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/reliability-of-crp-as-an-inflammatory-marker-in-patients-with-immune-mediated-inflammatory-diseases-imids-and-liver-dysfunction/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/reliability-of-crp-as-an-inflammatory-marker-in-patients-with-immune-mediated-inflammatory-diseases-imids-and-liver-dysfunction/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology